The mutagenicity of benzo[a]pyrene in mouse small intestine

被引:29
作者
Brooks, RA
Gooderham, NJ
Edwards, RJ
Boobis, AR
Winton, DJ
机构
[1] Addenbrookes Hosp, Cambridge Inst Med Res, Canc Res Campaign, Human Canc Genet Res Grp, Cambridge CB2 2XY, England
[2] Hammersmith Hosp, Royal Postgrad Med Sch, Dept Clin Pharmacol, London W12 0NN, England
关键词
D O I
10.1093/carcin/20.1.109
中图分类号
R73 [肿瘤学];
学科分类号
100214 ;
摘要
We have investigated the mutagenicity of benzo[a]pyrene (B[a]P) in small intestine using the Dlb-1 locus assay in the mouse. Administration of B[a]P by the oral and i.p. routes had markedly different effects on the number of Dlb-1 mutations and the pattern of induction of cytochrome P-4501A1 (CYP1A1). In Ahr-responsive animals i.p. injection resulted in marked induction in crypt cells along the length of the small intestine, with some induction in the villus cells. In contrast, after oral administration, CYP1A1 induction was evident only in the villus cells, and this declined distally. The intensity and speed of induction in Ahr-responsive animals was such that the genotoxic effect of a single injection of B[a]P could not be augmented by prior treatment with non-genotoxic inducers such as beta-napthoflavone and TCDD. Oral B[a]P treatment resulted in a decrease in the number of mutations when compared with the i.p. route. Studies in congenic Ahr-non-responsive versus Ahr-responsive mice indicated that induction of CYP1A1 was associated with increased numbers of Dlb-1 mutations. Mutation induction in Ahr-non-responsive mice in the absence of detectable CYP1A1 in either liver or small intestine indicates that an appreciable portion of B[a]P activation to a genotoxin must be by other than a CYP1A1 mediated route. These data show that B[a]P is a potent small intestinal mutagen at the Dlb-1 locus.
引用
收藏
页码:109 / 114
页数:6
相关论文
共 38 条
[1]   The role of individual susceptibility in cancer burden related to environmental exposure [J].
Bartsch, H ;
Hietanen, E .
ENVIRONMENTAL HEALTH PERSPECTIVES, 1996, 104 :569-577
[2]  
BOOBIS AR, 1977, MOL PHARMACOL, V13, P259
[3]  
BROOKS RA, 1994, CANCER RES, V54, P1665
[4]   LIPOXYGENASE-CATALYZED EPOXIDATION OF BENZO(A)PYRENE-7,8-DIHYDRODIOL [J].
BYCZKOWSKI, JZ ;
KULKARNI, AP .
BIOCHEMICAL AND BIOPHYSICAL RESEARCH COMMUNICATIONS, 1989, 159 (03) :1199-1205
[5]   Preferential formation of benzo[a]pyrene adducts at lung cancer mutational hotspots in P53 [J].
Denissenko, MF ;
Pao, A ;
Tang, MS ;
Pfeifer, GP .
SCIENCE, 1996, 274 (5286) :430-432
[6]   FREE-RADICAL EPOXIDATION OF 7,8-DIHYDROXY-7,8-DIHYDROBENZO[A]PYRENE BY HEMATIN AND POLY-UNSATURATED FATTY-ACID HYDROPEROXIDES [J].
DIX, TA ;
MARNETT, LJ .
JOURNAL OF THE AMERICAN CHEMICAL SOCIETY, 1981, 103 (22) :6744-6746
[7]   THE TIME-DEPENDENT INCREASE IN THE BINDING OF BENZO[A]PYRENE TO DNA THROUGH (+)-ANTI-BENZO[A]PYRENE-7,8-DIOL-9,10-EPOXIDE IN PRIMARY RAT HEPATOCYTE CULTURES RESULTS FROM INDUCTION OF CYTOCHROME P450IA1 BY BENZO[A]PYRENE TREATMENT [J].
EBERHART, J ;
COFFING, SL ;
ANDERSON, JN ;
MARCUS, C ;
KALOGERIS, TJ ;
BAIRD, WM ;
PARK, SS ;
GELBOIN, HV .
CARCINOGENESIS, 1992, 13 (02) :297-301
[8]   SHORT SYNTHETIC PEPTIDES EXPLOITED FOR RELIABLE AND SPECIFIC TARGETING OF ANTIBODIES TO THE C-TERMINI OF CYTOCHROME-P450 ENZYMES [J].
EDWARDS, RJ ;
SINGLETON, AM ;
MURRAY, BP ;
DAVIES, DS ;
BOOBIS, AR .
BIOCHEMICAL PHARMACOLOGY, 1995, 49 (01) :39-47
[9]  
FORKERT PG, 1988, MOL PHARMACOL, V34, P736
[10]   BENZO-A-PYRENE - ENVIRONMENTAL PARTITIONING AND HUMAN EXPOSURE [J].
HATTEMERFREY, HA ;
TRAVIS, CC .
TOXICOLOGY AND INDUSTRIAL HEALTH, 1991, 7 (03) :141-157